

Annexure 1 - Claims Rewritten to Show Amendments

1. (Canceled)

2.(Previously Amended) A method of preventing toxicity caused by a peptide fragment of apolipoprotein E having a molecular weight of at least 5kD to a cell comprising treating said cell with a compound wherein the compound is selected from the group consisting of polyvinyl sulfate, pentosan polysulfate, dextran sulfate, heparan sulfate and mixtures thereof.

Claims 3 -16 (Canceled)

17.(Previously Amended) A method of treating a mammal having a condition associated with toxicity caused by a peptide fragment of apolipoprotein E having a molecular weight of at least 5kD, comprising administering a composition comprising a pharmacologically effective amount of a compound, wherein the compound is selected from the group consisting of polyvinyl sulfate, pentosan polysulfate, dextran sulfate, heparan sulfate and mixtures thereof.

Claims 18 - 34 (Canceled)

35.(Amended) The method of Claim 17, wherein ~~inhibiting~~ treating a mammal having a condition associated with toxicity caused by a peptide fragment of apolipoprotein E toxicity comprises inhibiting binding of apolipoprotein E or fragments of apolipoprotein E to a cell.

36.(Original) The method of Claim 35, wherein the fragments of apolipoprotein E comprises residues 141-147 of apolipoprotein E.

37.(Amended) The method of Claim 17, wherein ~~inhibiting~~ treating a mammal having a condition associated with toxicity caused by a peptide fragment of apolipoprotein E toxicity

Response to Office Action
USSN 09/892,308 filed June 27, 2001

comprises inhibiting production of a peptide fragment of apolipoprotein E comprising residues 141-147 of apolipoprotein E.

38.(Amended) The method of Claim 17, wherein the condition is selected from the group consisting of Alzheimer's-type senile dementia, a condition associated with cerebral amyloidosis and ~~hyperlupidermia~~ hyperlipidemia.

39.(Original) The method of Claim 17, wherein the condition is selected from the group consisting of coronary heart disease, atherosclerosis, head injury, ischemic stroke, intracerebral hemorrhage, normal pressure hydrocephalus, HIV-associated dementia and HIV-associated peripheral neuropathy.

Claims 40-49 (Canceled)